Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects According to CD4+ T-Cell Counts at Presentation: The IMMUNEF Clinical Trial

摘要

BackgroundLongitudinal characterization of immune recovery in the first-phase of antiretroviral therapy (ART) is poorly described. We compared immune kinetics in individuals who were diagnosed early or late with HIV-1 infection, (thus commencing ART with different CD4⁺ T-cell counts), in order to investigate possible mechanisms involved in subsequent poor immune recovery.